I think it is safe to say Mallinckrodt was the company ElSohly and UM were working with before Nemus on their CINV/THC indication. As far as why the deal is terminated, like Vinpat said, it could be for different reasons.
UofM and Elsohly have a very good deal with Nemus in terms of protecting their IP and ensuring they get Paid their fair Share if the indications make it to the market. Maybe Mallinckrodt didn't like the demands coupled with the risks associated with cannabinoids. But again, look at the agreements between UMiss and NMUS; locked in and exclusive. The window has closed on anyone else getting their hands on the IP and doing something with it. Wouldn't be a bad question to ask IR and confirm this though....
CJ, I like your Style. You ask Tough questions like Vinpat. But, I think it is harsh to say NMUS is misrepresenting the data on their THC prodrug suppository for CINV. I am sure more research has occurred over the period of time between the Mallinckrodt deal and present day. It might of built off earlier work, and set similar metrics to measure efficacy, but your making it sound like they Copy and Pasted 10-20 year old studies and called them 'internal data'....
News 
Market Data 
Discover 
[/url] 
